Noticias y eventos de Becton Dickinson and Co (BDX)BDXBecton Dickinson and Co

BD Reports Positive Nine-Month Results for Revello Vascular Covered Stent

BD announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, global lead principal investigator for AGILITY, the results demonstrated strong safety and effectiveness outcomes in patients with iliac artery disease, a common form of peripheral artery disease, or PAD. The study met its primary composite endpoint for the treatment of iliac artery disease and adds to the growing body of clinical evidence supporting the continued evaluation of the Revello Vascular Covered Stent. The device is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac arteries. Iliac artery disease can reduce blood flow to the legs and feet and potentially cause symptoms such as leg pain, cramping, impaired mobility and reduced quality of life. As treatment options evolve, physicians continue to seek durable solutions that provide sustained vessel patency and favorable long-term outcomes, particularly for patients with complex iliac artery anatomy. The AGILITY iliac cohort enrolled 120 patients at 28 investigational sites in the United States, Europe, Australia and New Zealand. Through nine months of follow-up, treatment with the Revello Vascular Covered Stent resulted in: Composite safety and effectiveness endpoint met with a failure rate of 2.8%, significantly below the 19% prespecified performance goal; 97.2% primary patency 98.3% freedom from clinically driven target lesion revascularization; and No device- or procedure-related deaths, target limb major amputations, or unanticipated serious adverse device effects.

Becton Dickinson Partners with U.S. Government for $19B Manufacturing Expansion

Becton Dickinson announced a partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day. The agreement supports significant investments in U.S. manufacturing, innovation and end-to-end production capabilities. Through this partnership, BD intends toinvest $19B in the U.S. over several years, including capital, operational and supply chain investments. BD also intends to direct $3B of the overall investment toward U.S. manufacturing expansion focused on strategic production sites across the country. The partnership expands end-to-end U.S. production by approximately 5B essential medical consumables annually, raising BD's share of domestically supplied essential medical consumables to roughly 80 percent. The company will manufacture 100% of BD needles used in America domestically using American-made steel. The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones. Because the final tariff rates, product scope and effective timing have not yet been determined, BD is not currently quantifying the financial impact of the agreement. The company expects to provide additional information when the Section 232 tariffs are finalized.

Becton, Dickinson Appoints Arthur Hu as Chief Information Officer

Becton, Dickinson and Company (BDX) announced that Arthur Hu has been named executive vice president and chief information and digital officer, effective September 30. Hu brings more than 25 years of experience leading global technology, digital and business transformation initiatives at scale. He joins BD from Lenovo Group (LNVGY), where he most recently served as senior vice president, global chief information officer and chief technology and delivery officer for the Solutions and Services Group.